Advesya, a French/Swiss clinical-stage biotech company founded in 2020, is transforming the fight against cancer and autoimmune diseases. Building on years of academic research, advesya’s innovative work targets IL-1RAP, a unique antigen, which is upregulated in various cancers and autoimmune conditions.
Interleukin-1 receptor associated protein (IL-1RAP/IL-1R3) serves as a crucial point of convergence for IL-1-related cytokines. It primarily resides on the plasma membrane, where it functions as an essential co-receptor for IL-1R signal transduction. Additionally, IL-1RAP interacts with ST2 (IL-33R) and the IL-36 receptor. Notably, it is the sole shared node among the receptor complexes of IL-1 family of cytokines.
Given the strong association of IL-1-related cytokines with chronic inflammation, cancer, and autoimmune diseases, the upregulation of IL-1RAP and the activation of the pathway in several indications present a significant therapeutic opportunity, particularly since it is poorly expressed in healthy tissue.
advesya
© 2024 advesya | All rights reserved
